Phase2a Primaquine Dose Escalation Study

PHASE2CompletedINTERVENTIONAL
Enrollment

81

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions
Malaria
Interventions
DRUG

dihydroartemisinin-piperaquine

DRUG

0.125 mg/kg Primaquine

DRUG

0.5 mg/kg Primaquine

DRUG

0.25 mg/kg Primaquine

DRUG

0.0625 mg/kg Primaquine

Trial Locations (1)

Unknown

Malaria Research and Training Centre, Bamako

All Listed Sponsors
collaborator

Malaria Research and Training Center, Bamako, Mali

OTHER

collaborator

Shoklo Malaria Research Unit

OTHER

collaborator

Mahidol Oxford Tropical Medicine Research Unit

OTHER

collaborator

Bill and Melinda Gates Foundation

OTHER

collaborator

Wellcome Trust

OTHER

lead

University of California, San Francisco

OTHER

NCT01743820 - Phase2a Primaquine Dose Escalation Study | Biotech Hunter | Biotech Hunter